EMBL-EBI | Chemical Biology | ChEBI
Example searches: iron*, InChI=1S/CH4O/c1-2/h2H,1H3, caffeine | Advanced Search
| Formula | C21H20F5N3O4 |
| Net Charge | 0 |
| Average Mass | 473.398 |
| Monoisotopic Mass | 473.13740 |
| SMILES | COc1c([C@H]2[C@H](C(=O)Nc3ccnc(C(N)=O)c3)O[C@@](C)(C(F)(F)F)[C@H]2C)ccc(F)c1F |
| InChI | InChI=1S/C21H20F5N3O4/c1-9-14(11-4-5-12(22)15(23)16(11)32-3)17(33-20(9,2)21(24,25)26)19(31)29-10-6-7-28-13(8-10)18(27)30/h4-9,14,17H,1-3H3,(H2,27,30)(H,28,29,31)/t9-,14-,17+,20+/m0/s1 |
| InChIKey | XSQUJFKRXZMOKA-PAFIKIDNSA-N |
| Wikipedia |
|---|
| Roles Classification |
|---|
| Biological Roles: | non-narcotic analgesic A drug that has principally analgesic, antipyretic and anti-inflammatory actions. Non-narcotic analgesics do not bind to opioid receptors. voltage-gated sodium channel blocker Any sodium channel blocker that interferes with the activity of voltage-gated sodium channels. |
| Application: | non-narcotic analgesic A drug that has principally analgesic, antipyretic and anti-inflammatory actions. Non-narcotic analgesics do not bind to opioid receptors. |
| ChEBI Ontology |
|---|
| Outgoing Relation(s) |
| suzetrigine (CHEBI:233446) has role non-narcotic analgesic (CHEBI:35481) |
| suzetrigine (CHEBI:233446) has role voltage-gated sodium channel blocker (CHEBI:38634) |
| suzetrigine (CHEBI:233446) is a difluorobenzene (CHEBI:38582) |
| suzetrigine (CHEBI:233446) is a monomethoxybenzene (CHEBI:25235) |
| suzetrigine (CHEBI:233446) is a oxolanes (CHEBI:26912) |
| suzetrigine (CHEBI:233446) is a primary carboxamide (CHEBI:140324) |
| suzetrigine (CHEBI:233446) is a pyridinecarboxamide (CHEBI:25529) |
| suzetrigine (CHEBI:233446) is a secondary carboxamide (CHEBI:140325) |
| IUPAC Name |
|---|
| 4-({[(2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-yl]carbonyl}amino)pyridine-2-carboxamide |
| INNs | Source |
|---|---|
| suzétrigine | WHO MedNet |
| suzetrigine | WHO MedNet |
| suzetrigina | WHO MedNet |
| suzetriginum | WHO MedNet |
| Synonyms | Source |
|---|---|
| VX-548 | DrugBank |
| VX548 | DrugBank |
| VX 548 | DrugBank |
| 4-[(2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-4,5-dimethyl-5-(trifluoromethyl)oxolane-2-amido]pyridine-2-carboxamide | ChEBI |
| Brand Name | Source |
|---|---|
| JOURNAVX | ChEBI |
| Manual Xrefs | Databases |
|---|---|
| DB18927 | DrugBank |
| D12860 | KEGG DRUG |
| Suzetrigine | Wikipedia |
| WO2021113627 | Patent |
| Registry Numbers | Sources |
|---|---|
| CAS:2649467-58-1 | KEGG DRUG |
| Citations |
|---|